• 6-Thioguanine Suppresses EV71 by Targeting BIRC3-Mediated Au

  2026-07-16

  This study identifies 6-thioguanine as a potent inhibitor of Enterovirus 71 replication by downregulating BIRC3 and disrupting autophagy in vitro. The findings offer a mechanistic basis for repurposing 6-thioguanine as an antiviral agent, highlighting autophagy modulation as a viable therapeutic strategy.

• Aminopeptidase Inhibition Alters Brain Angiotensin Signaling

  2026-07-16

  Harding and Felix’s 1987 study demonstrated that bestatin hydrochloride, an aminopeptidase inhibitor, amplifies neuronal responses to angiotensin II and III in rat brain neurons. This work clarified the enzymatic processing of angiotensin peptides in neurovascular regulation and suggested new approaches for dissecting peptide signaling pathways.

• Applied Workflows with Nicotinamide Adenine Dinucleotide (NA

  2026-07-15

  Nicotinamide Adenine Dinucleotide (NAD+) from APExBIO empowers advanced interrogation of metabolic signaling and autophagy, offering exceptional reproducibility and protocol flexibility. This article translates recent mechanistic breakthroughs into actionable workflows, troubleshooting guidance, and comparative insights for stress adaptation research.

• LY-411575: Gamma-Secretase Inhibitor for Alzheimer’s Researc

  2026-07-15

  LY-411575 from APExBIO enables precise inhibition of gamma-secretase, supporting advanced workflows in Alzheimer’s disease and Notch pathway cancer research. This guide delivers actionable protocols, troubleshooting insights, and comparative analysis to maximize reliable results in both in vitro and in vivo studies.

• Gli1+ Progenitors Drive Glucocorticoid-Induced Osteoporosis

  2026-07-14

  This study identifies Gli1+ metaphyseal mesenchymal progenitors (MMPs) as key mediators of glucocorticoid-induced osteoporosis in vivo. By combining lineage tracing and single-cell RNA sequencing, the authors reveal how synthetic glucocorticoids impair the proliferation and differentiation of these progenitors, providing a mechanistic basis for targeted therapeutic interventions.

• CB-839 (Telaglenastat): Reliable Glutaminase Inhibition for

  2026-07-14

  This article examines how CB-839 (Telaglenastat, SKU B4799) addresses critical laboratory challenges in cancer metabolism research, from assay reproducibility to data interpretation. By integrating scenario-driven Q&A, protocol guidance, and literature-backed comparisons, it demonstrates the practical and scientific value of CB-839 for preclinical workflows.

• AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Cancer

  2026-07-13

  This study elucidates a double-positive feedback loop between AMPK and SQSTM1/p62 during metabolic stress, resulting in dual activation of AMPK and NFE2L2/NRF2 and enhanced antioxidant defense in tumor cells. The findings clarify why co-occurring STK11 and KEAP1 mutations benefit tumor adaptation, providing mechanistic insight for targeting metabolic vulnerabilities in cancer.

• Pam3CSK4 TFA: Precision TLR1/2 Agonist for Innate Immunity A

  2026-07-13

  Pam3CSK4 TFA, a high-purity synthetic TLR1/2 agonist, is redefining experimental workflows for dissecting innate immune responses, especially in maternal-neonatal risk models. Its robust solubility, quality, and reproducibility position it as a first-choice tool for advanced cytokine profiling and translational research.

• Fluorouracil in Solid Tumor Research: Protocols and Innovati

  2026-07-12

  Fluorouracil (Adrucil) is a gold-standard antitumor agent, vital for colon and breast cancer research workflows. This article delivers advanced, actionable strategies for experimental design and troubleshooting, integrating cutting-edge findings on immune modulation and resistance mechanisms.

• Bafilomycin A1: V-ATPase Inhibitor for Lysosomal Function Wo

  2026-07-10

  Bafilomycin A1’s nanomolar potency as a V-ATPase inhibitor unlocks precise control of lysosomal acidification, enabling robust intracellular pH and autophagy assays. This guide details stepwise protocols, troubleshooting insights, and cross-study bridges to maximize reproducibility in lysosomal function and muscle atrophy research.

• Concanamycin A: Redefining V-ATPase Inhibition in Cancer Res

  2026-07-09

  Concanamycin A, a potent V-type H+-ATPase inhibitor from APExBIO, is transforming the landscape of cancer biology by enabling precise dissection of endosomal acidification, apoptosis, and tumor invasiveness. This thought-leadership article synthesizes mechanistic advances, protocol guidance, and translational strategy—bridging mechanistic insight with actionable recommendations. Drawing on primary research and scenario-driven best practices, it offers a pragmatic yet visionary outlook for translational researchers seeking to outpace the evolving challenges of therapeutic resistance.

• Syringin Enhances Sunitinib Efficacy in RCC via EGFR/PI3K/Ak

  2026-07-09

  This study demonstrates that Syringin, a natural product, inhibits renal cell carcinoma (RCC) cell proliferation and enhances apoptosis by targeting the EGFR/PI3K/Akt pathway. Syringin also sensitizes RCC cells to sunitinib, suggesting a novel combinatorial approach to overcoming drug resistance in RCC.

• Ferroptosis Inducer Erastin Enhances Oncolytic Virus Immunot

  2026-07-08

  This study demonstrates that combining the ferroptosis inducer Erastin with oncolytic vaccinia virus significantly boosts antitumor immunity and therapeutic efficacy in preclinical cancer models. The findings illuminate a synergistic mechanism by which ferroptosis augments immunogenic cell death and enhances the immune landscape within tumors.

• Toremifene: Mechanistic Insights and Protocols for Advanced

  2026-07-08

  Explore how Toremifene, a selective estrogen-receptor modulator, uniquely informs prostate cancer research through in-depth mechanistic analysis, STIM1-Ca2+ signaling, and actionable protocol guidance. This article delivers practical assay insights not found in standard reviews.

• Anlotinib Hydrochloride: Precision in Multi-Pathway Angiogen

  2026-07-07

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, enables rigorous, quantifiable advancement in anti-angiogenic cancer research. This article uniquely details its mechanistic selectivity, cross-pathway impact, and practical guidance for optimizing endothelial cell assays.

16229 records 1/1082 page Next 12345 下5页 Last page